Updates | Elegaiter

Elegaiter Updates

Check out ourlatest updates

Elegaiter has obtained domestic and international certifications and patents.

Check out our news, papers, and patents.

2026-09-20

Elegaiter Proves Value at 'PCA KOREA SUPER SERIES'

The 'PCA KOREA SUPER SERIES', one of the largest fitness competitions in South Korea, was successfully held over two days from September 19th to 20th. During the event, our Elegaiter team co-operated the 'Elegaiter Gait Analysis Booth' in collaboration with 'Joabro Conditioning'. It was a deeply meaningful opportunity to directly connect with fitness professionals and experts—the primary target audience for our product—and listen closely to their vivid, firsthand voices. This field participation was particularly significant as it allowed us to identify the critical need among fitness center operators for increasing the average sales per customer (unit price), while offering a clear, data-driven solution. By shifting away from traditional methods that rely heavily on a trainer's subjective assessment, Elegaiter visualizes and proves a member's movements through quantitative data. This experience has strengthened our confidence that fitness centers can successfully market their programs as premium services. Numerous industry insiders who visited our booth deeply resonated with the necessity of data-driven consultation and expressed overwhelming interest. While continuously advancing Elegaiter, our proprietary AIoT-based digital gait healthcare service, CiKLux is also preparing for the upcoming Wadiz crowdfunding campaign set to open at the end of September. As a special reward, we plan to provide close, customized support for the initial backers by implementing the specific gait analysis features and service developments they desire over a three-month period. Moving forward, we remain committed to technological innovation that listens to the voices on the ground, establishing ourselves as the most reliable partner growing alongside the fitness and healthcare industries. Thank you.

2026-09-16

CEO Invited as an Official Lecturer at 'Biohealth Academy'

## [Company News] CEO Hyun-sang Cho Invited as an Official Lecturer at the Chungbuk Bio-humanities and Academic Convergence Institute's 'Biohealth Academy' From September 16th to 17th, the ‘Biohealth Regulation and Licensing Practical Training: Clinical Trial Design and Major Considerations for Commercializing Pharmaceuticals, Medical Devices, and Digital Medical Products’ course was successfully conducted as part of the 'Biohealth Academy' program hosted by the Chungbuk Bio-humanities and Academic Convergence Institute. For this training course, Hyun-sang Cho, CEO of CiKLux, was invited as an official lecturer to pass down in-depth practical know-how to biohealth majors and prospective job seekers looking to enter the industry. CEO Hyun-sang Cho focused heavily on clinical trial design strategies indispensable for successfully commercializing not only conventional pharmaceuticals and medical devices but also digital medical products—a major hot topic in the current market. Rather than leaning on abstract theories, he generously shared core field-driven considerations that can be applied immediately in the industry, receiving highly enthusiastic responses from the trainees. Trainees who participated in the session sent expressions of gratitude, stating, "Being exposed to such specific, professional guides that can be put to work right in the field was incredibly helpful for our future career development." We send our most sincere encouragement to all the trainees who are passionately undergoing this extensive training curriculum to become the next leaders of the biohealth industry. We genuinely bless each of you, hoping that the knowledge and practical wisdom gained during these two days will serve as a fertile foundation to achieve your dreams and grow into brilliant assets to the bio sector. CiKLux develops its proprietary AIoT-based gait digital healthcare service, Elegaiter, while simultaneously taking dedicated steps to nurture global and domestic clinical trial experts, providing unsparing support so that our industry and its members can grow together. We will continue to be a dependable partner, advancing alongside the bio and healthcare industries through professional knowledge sharing and continuous technological innovation. Thank you.

2026-09-15

CEO Takes the Stage! '2026 NextBio Scale-up Academy'

Hyun-sang Cho, CEO of CiKLux, was invited as a keynote speaker and delivered a lecture at the '2026 NextBio Scale-up Academy (BioBiz Jumpstart)' on September 15. In this program designed to support the growth of startups in the bio and medical sectors, CEO Cho presented on the topic of "Understanding the Full Lifecycle of Digital Healthcare Development." The lecture provided a clear overview of core practical processes that digital healthcare companies frequently find challenging, including product planning, software (SW) development, SaMD (Software as a Medical Device) classification, clinical validity verification using algorithms and RWE (Real-World Evidence), and regulatory approval procedures. CEO Cho is a recognized clinical trial expert who continuously leads educational sessions for various specialized institutions, including clinical training programs for the Korea National Enterprise for Clinical Trials (KONECT). His lecture at this event once again demonstrated CiKLux’s industry-leading expertise, drawing significant engagement from biotech professionals in attendance. 'Elegaiter', the gait analysis and exercise solution service currently being advanced by the CiKLux team, is being developed based on this comprehensive expertise that spans from initial clinical planning to validation and regulatory approval. Leveraging its specialized technical capabilities and industry knowledge, CiKLux plans to further refine Elegaiter's features to deliver a highly sophisticated service to the clinical trial market. We look forward to the continued interest and support of our customers and partners.

2026-09-14

Our Journey to the 2nd Round Presentation

Elegaiter, the new product currently under development by CiKLux, has completed its Phase 2 face-to-face presentation evaluation, marking the final stage of the '2026 AI Small Business Innovation Support Program'. The program saw intense competition in the initial phase, recording a high 12:1 ratio for the Phase 1 document screening. Having successfully advanced, CiKLux's CEO took the stage as the primary presenter for the Phase 2 evaluation, presenting the company's technical capabilities as a specialized clinical research organization (CRO) alongside the market potential of the product. The presentation was delivered strictly within the 10-minute time limit. While the panel of judges raised highly technical and sharp questions, the session served as an opportunity to objectively demonstrate Elegaiter’s technological value and distinct advantages through clear, expertise-backed responses. Members of the internal team present at the site were able to reconfirm the core competitiveness and value of our product. Upon final selection for this support program, the secured resources will be fully allocated toward advancing Elegaiter’s service capabilities and executing aggressive marketing campaigns for market entry. This initiative is expected to elevate the product as a driver of digital transformation in the clinical trial market while significantly broadening touchpoints with partners and clients. Having successfully navigated both the competitive document screening and the critical face-to-face evaluation, the entire team now awaits a positive final outcome. We appreciate the continued interest and support from our employees and partners as Elegaiter prepares for its next milestone. Further updates will be shared as soon as the final results are announced.

2026-09-09

Meeting Elegaiter’s Future at 'Try Everything 2026'

[Seoul DDP = CiKLux Newsroom] The CiKLux team, developers of the gait analysis and exercise solution service 'Elegaiter', visited the Dongdaemun Design Plaza (DDP) to participate in 'Try Everything 2026', Seoul's premier startup festival in September, actively seeking to discover new partner firms. During the event, the CiKLux team held consecutive 30-minute, close-knit 1:1 business meetings with representatives from major public institutions and large enterprises. This provided a significant opportunity to widely introduce the core technological capabilities and clinical value of their new product, Elegaiter, ahead of its market launch later this year, while actively seeking reliable partners to create strategic synergies. Notably, this year's DDP event combined tech demonstrations for startups with various cultural and entertainment elements, including an appearance by the globally rising virtual idol group 'PLAVE', adding to the vibrancy of the festival. An internal representative present at the site noted that the business trip served as a multifaceted opportunity to achieve core promotional goals while directly experiencing the latest cultural trends and gaining broader market insights. Leveraging the active partnerships forged with major enterprises and institutions during this event, CiKLux plans to diversify Elegaiter's distribution channels and aggressively expand its market share in the coming months.

2026-08-21

CiKLux Successfully Concludes 'KHF 2026' Exhibition via Ewha Medical Center Joint Pavilion, Drawing Immense Interest for AIoT Gait Wellness Solution 'Elegaiter'

• Selected as an enterprise by the Ewha Medical Center Open Innovation Lab to showcase at COEX 'KHF 2026' • 'Elegaiter,' newly launched this past July, offered live trials to over 50 visitors, providing real-time gait monitoring reports • Accurately detected gait imbalances across all age groups (10s to 80s); accelerated cross-industry partnership discussions for original technology [COEX, Seoul = CiKLux Newsroom] CiKLux, an AIoT-based digital healthcare startup, announced the successful wrap-up of its live demonstration and exhibition for 'Elegaiter,' a trailblazing gait wellness solution, at the K-HOSPITAL+HEALTH TECH FAIR 2026 (KHF 2026) held at COEX, Seoul, from August 19 to 21. CiKLux participated in this premier domestic digital healthcare exhibition as a selected promising enterprise of the Ewha Medical Center Open Innovation Lab. The company occupied a prominent space within the 'Hospital R&D Innovation Zone,' which showcases achievements bridged between clinical infrastructure and startup commercialization. The on-site booth experienced an enthusiastic response. Over the three-day event, more than 50 attendees—ranging in age from teenagers to octogenarians—experienced the Elegaiter system firsthand by walking on a treadmill for just 3 minutes. Powered by its patented original technology 'JAWS,' Elegaiter is an innovative AIoT solution that analyzes the instantaneous power consumption of a treadmill's motor to track walking balance and risk signals in real-time, eliminating the need for cumbersome wearables or cameras. Participants expressed immense fascination upon receiving their customized 'Real-Time Gait Monitoring Report' generated immediately after the trial. The system dynamically captured underlying physical imbalances with precision: for instance, it visually graphed the compromised walking symmetry of a user with a past torn meniscus, and vividly highlighted a 2-degree rightward lateral tilt in another user's posture alignment. On-site trial participants remarked, "It is incredibly fascinating to see hidden musculoskeletal instability and gait imbalances translated into intuitive, real-time visual data right before our eyes." Furthermore, KHF 2026 served as a high-value networking hub that underscored the infinite cross-industry scalability of CiKLux's core technology. The booth hosted successive strategic meetings with prospective partner companies from fields that initially seemed unrelated, including fitness centers, senior care (dementia prevention), education, and insurance. The discovery of synergistic pathways to repurpose and integrate the raw data analytics into diverse service models yielded highly encouraging results. "Following our official market launch this past July, we are thrilled that Elegaiter has gained such profound public interest and clinical validation at KHF 2026," said Hyunsang Cho, CEO of CiKLux. "We remain committed to transforming repetitive treadmill workouts into engaging, personalized wellness content. Moving forward, we will actively accelerate open innovation partnerships both domestically and globally to expand daily gait analytics into comprehensive preventative healthcare.

Updates CiKLux Successfully Concludes 'KHF 2026' Exhibition via Ewha Medical Center Joint Pavilion, Drawing Immense Interest for AIoT Gait Wellness Solution 'Elegaiter' image

2026-08-10

Visit Us at KHF 2026: Booth F50

We are pleased to introduce our core technology, CiKLux Elegaiter, at the K-Hospital Fair 2026 (KHF 2026) from August 19th to 21st at COEX. You can visit our exhibition at Booth F50, hosted within the Ewha Womans University Mokdong Hospital Open Laboratory Joint Pavilion. Presenting our hard work alongside leading healthcare pioneers at this prestigious event fills our team with immense excitement and a strong sense of purpose. At this year's exhibition, we will showcase the foundational data and hardware versatility of Elegaiter, which is currently undergoing real-world application across fitness networks like Joabro Fitness. We look forward to connecting with digital health software developers who can transform our tracking data into clinical evidence, and hospital officials interested in exploring new possibilities for smart rehabilitation and wellness infrastructure. Free pre-registration is available until August 18th, so please secure your complimentary pass before the deadline. • Event: K-Hospital Fair 2026 (KHF 2026) • Date: 10:00 – 18:00 August 19 (Mon) – August 21 (Wed), 2026 (※ Closes at 17:00 on Friday) • Location: 3th floor C, D hall COEX, Seoul, https://linkonbiz.com/product/14788 • Booth Number: F50 Ewha Womans University Mokdong Hospital Open Lab Joint Pavilion • Free Pre-registration by Tuesday, August 18th https://khospital.org/registration/#/pre-reg/891 Thank you.

2026-08-05

📢 Hey Tired Office Workers! 'Elegaiter' Now on Naver Smart Store (feat. KHF Special Offer) 💥

Do you find yourself collapsing onto the couch right after work? 🙋‍♀️ We totally get it—you know you need to work out, but even breathing feels like a chore when you're exhausted. After burning out completely at the office today, you might ask, "Who's gonna take care of my body?" Don't worry, Elegaiter will take care of you! 🐊✨ (It sounds like an alligator, but it's actually your ultimate body caretaker!) Now you can easily purchase Elegaiter on the Naver Smart Store! To celebrate the launch and the KHF period from August 19th to 21st, we are running an exclusive, limited-time additional discount. Don't miss this chance to invest in your wellness! Search 'Elegaiter JAWS' on Naver to shop right now! #ciklux #elegaiter #NaverSmartStore #OfficialLaunch #ShopNow #NewArrival #Kbeauty #TrendingItem #KHF2026 #OfficeWorkerLife #BurnoutCure #LimitedTimeOffer #ShopNow #SelfCare

2026-08-03

Lectured at 2026 2nd KoNECT CRA Introductory Practical Training Course

From August 3rd to 7th, the "2026 2nd Clinical Research Associate (CRA) Introductory Practical Training Course" hosted by the Korea National Enterprise for Clinical Trials (KoNECT) was successfully conducted. Continuing from the previous sessions, CiKLux's very own CEO Hyunsang Cho, along with Senior Vice President Sung-eun Kim and Director Seon-nyeo Lee, were invited as official lecturers to share their extensive real-world expertise. This second session held an incredibly special meaning for our team. A new CiKLux team member—who actually completed the 1st session of this exact same course back in February and subsequently joined our company—participated in this session as an assistant lecturer. During the highly challenging yet critical EMR (Electronic Medical Record) review and SDV (Source Data Verification) practical sessions, our team member provided close support to the new trainees, sharing fresh insights and empathetic guidance from the perspective of someone who was recently in their exact same shoes. While building and expanding our AIoT-based digital gait healthcare platform, Elegaiter, CiKLux Inc. remains deeply committed to advancing professional clinical research ecosystems and fostering the growth of our talented team members.We will continue to drive growth in the bio-healthcare industry through professional knowledge-sharing and continuous technological innovation. Thank you.

2026-07-22

CiKLux CEO Invited as Key Speaker for the K-Biohealth Regional Center Startup Program

CiKLux CEO Hyunsang Cho Invited as Key Speaker for the K-Biohealth Regional Center Startup Program Hello from CiKLux. We are proud to announce that our CEO was officially invited as a key speaker for the "1st Startup Capacity Building Program," hosted by the K-Biohealth Regional Center Support Project at Cheongju SB Plaza on July 21st. The training program was tailored for promising startups and innovators in the biohealth sector. Our CEO led the practical session on "Biohealth Regulations and Licensing/Approvals," delivering a high-impact lecture packed with real-world insights. By sharing strategic know-how on navigating complex medical device regulatory frameworks and licensing procedures, the lecture received enthusiastic feedback and high praise from the attending entrepreneurs. CiKLux will continue to demonstrate technological leadership in pioneering the next-generation digital healthcare market, while remaining dedicated to sharing expert knowledge to foster growth across the wider biohealth industry ecosystem. Thank you.

2026-07-21

CiKLux-KoNECT Course on Medical Product Design

"No matter how excellent a medical technology is, it cannot enter the market if it fails in 'clinical trial design.'" Have you felt overwhelmed by the complex barriers of clinical trials, even after developing innovative medical technologies and devices? If you take the wrong direction in the early planning stage, millions of dollars and years of time will go down the drain. In this [KoNECT-CiKLux] special lecture, we reveal the 'Winning Clinical Strategy Blueprint' to bring your lab-confined technology to market in the fastest and safest way possible. Minimize trial and error, and maximize your commercialization success rate—all in just one day! Based on our extensive eight years of experience in strategic consulting, CiKLux Inc. is proud to announce the return of our highly sought-after professional training course. Following last year's success, we have once again partnered with the Korea National Enterprise for Clinical Trials (KoNECT) to open a comprehensive 1-day (6-hour) course on clinical trial design tailored for the commercialization of medical technologies, including pharmaceuticals, medical devices, and digital health products. Throughout our years of driving business forwarding, we have frequently observed that a lack of foundational understanding among a client’s project participants can lead to significant setbacks. In project management, the most critical risks often stem from "not knowing what you don't know" or acting on flawed assumptions of knowledge. To mitigate these risks, this course is uniquely designed compared to traditional programs. While highly beneficial for direct clinical trial practitioners, it specifically targets non-clinical professionals—including executives, corporate planners, and business developers—who oversee or support these healthcare initiatives. Stay tuned for more updates as CiKLux continues to bridge the gap between medical innovation and successful market commercialization. https://lms.konect.or.kr/web/course/courseView.do?eduCd=K000000001202607210002&eduCertifiedYn=N&category1= 🎯 Key Takeaways from this Lecture (Learning Objectives) • Prevent Wasted Time and Money: Completely block common mistakes and critical decision-making errors in the early planning stage. • Master Clinical Trials: Grasp the entire structure and key steps of complex clinical trials through an easy-to-understand breakdown. • Strengthen Practical Strategies: Build the capability to independently design the optimal clinical and commercialization strategies tailored to your company's R&D technology. 📘 Main Curriculum 1. MedTech Commercialization & Market Entry Strategy • Understanding the medical technology commercialization process • Identifying entry strategies for innovative medical devices & new health technologies 2. Understanding Clinical Trial Procedures & Regulations • Regulatory frameworks and procedures for pharmaceuticals & medical devices • Analyzing clinical trial budget structures 3. Clinical Trial Design & Statistical Approach • Key considerations in clinical design and sample size calculation • Establishing statistical concepts & data collection/validation 4. Latest Trends & Case Studies • Real-world cases of Digital Therapeutics (DTx) clinical trials and linked commercialization strategies

2026-07-10

Successfully Closes Wadiz Funding with 519% Achievement!

We are thrilled to announce that our real-time gait analysis system, 'Elegaiter,' has successfully wrapped up its Wadiz crowdfunding campaign, achieving an incredible 519% of our original goal thanks to your overwhelming support! This funding campaign was a meaningful opportunity to share the data-driven future of fitness and healthcare with so many supporters. We extend our deepest gratitude to everyone who believed in Elegaiter's innovative technology and showered us with immense support. To repay your trust, we will ensure rigorous quality control and preparation to deliver the absolute best product to your doorstep. Please stay tuned for the upcoming journey of Elegaiter and CiKLux as we continue to lead the digital healthcare market. Thank you.